Last modified: April 11, 2024
Quick Facts
  • certificate with a ribbon icon below
    • Swiss Medical Certificate
    • Certificate in Pathology
    • Heidelberg University, Medical Biometrics
    • University of Regensburg, M.D.
  • membership card and identification icon
    • Frankfurt Institute for Advanced Studies (Senior fellow)
    • Hamburg Medical Association
    • German Medical
  • plus sign in a circle icon
    • Pathology
    • Research
    • Genomics
    • Proteomics
    • Pleural Mesothelioma

About Dr. Wild

Dr. Peter J. Wild has been director of the Dr. Senckenberg Institute of Pathology, University Hospital Frankfurt since 2018 and has been affiliated with the Wild Lab, University Hospital Frankfurt MVZ GmbH, since 2019.

He often shares his expertise as a contributing writer for The Mesothelioma Center at, the nation’s most trusted mesothelioma resource.

Wild served as a medical officer in the Department of Pathology and Molecular Pathology at the University Hospital Zurich from 2010 to 2012. He was appointed assistant professor for systems pathology and became an attending physician at University Hospital Zurich in 2012.

As chief investigator and director of the laboratory for high-throughput genomics and proteomics at University Hospital Zurich, Wild was responsible for the integration of next-generation sequencing and mass spectrometry techniques into clinical practice.

In 2020, Wild was named senior fellow at the Frankfurt Institute for Advanced Studies, Frankfurt am Main. In 2022, Wild published research on the prevalence and impact of the small duct and large duct types on survival in patients with intrahepatic cholangiocarcinoma.

Under the leadership of Wild, the Dr. Senckenberg Institute has established itself as one of the first digital institutes for pathology. His goal is to make diagnostic and treatment decisions more precise for clinical physicians by utilizing genomic methods and medical knowledge made possible by big data.

Through his laboratory, better personalized medicine is being uncovered through pathological findings, molecular pathological data, annotated digital histological images and known interactions between genetic changes and drugs.

Wild believes more accurate predictions can be made in the future for each individual patient.